Study Of TL-895 In Subjects With Myelofibrosis

Overview

About this study

This purpose of this study is to evaluate TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Adults ≥ 18 years of age

- Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating
physician according to the World Health Organization (WHO) criteria

- Palpable spleen measuring ≥ 5 cm below the LLCM or spleen volume of ≥ 450 cm³ by MRI or
CT scan assessment

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

- Adequate hematologic, hepatic, and renal functions

Exclusion Criteria:

- Prior treatment with any BTK or BMX inhibitors

- Cohorts 1 and 2 - Prior treatment with JAKi within 21 days of the Screening MRI/CT
scan. Subjects in Cohort 3 must not have received JAKi

- Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study
treatment

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thanai Pongdee, M.D.

Open for enrollment

Contact information:

Kay Bachman

5072845689

bachman.kay@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Cecilia Arana Yi, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available